Global Multiple Sclerosis Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

October 2017 | 204 pages | ID: G74C2B152B3EN
Precision Business Insights (PBI)

Abstracts

Global Multiple Sclerosis Drugs Market:

Global multiple sclerosis drugs market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for multiple sclerosis drugs projected to reach US$ XX Mn by 2023.

Multiple Sclerosis (MS) is a demyelinating disease that affects spinal cord and brain. Multiple sclerosis damages myelin sheath, material that surrounds and protects nerve cells. This damage blocks or slows down messages between brain and body. The exact cause of the Multiple Sclerosis disease is unknown but it is an autoimmune disease. Some of the major problems include doubled vision, psychological, mental disturbances and not having coordination in body movements. Most of the people diagnosed with MS are between the age 20 to 50 years and it can occur in young children and significantly older adults.

The unmet need of drugs for the treatment of multiple sclerosis, extensive R&D pipelines and prevalence of the disease are driving factors for the market growth of Multiple Sclerosis drug market. According to the Atlas MS, there are about 2.3 million people are with multiple sclerosis, and most of the patients are not diagnosed with multiple sclerosis and certain parts of the world due to the lacking of healthcare infrastructure and unawareness. The advancements in the biomedical science about to create a profitable opportunities for multiple sclerosis drug makers in near future. However patent expiry of the key drugs is key restraint for multiple sclerosis market, In addition strengthening of regulatory requirements and procedures also making difficulties in steady market growth.

Multiple sclerosis drug market can be segmented into mode of administration, distribution channel, and drug class

Based on route of administration, multiple sclerosis drugs market can be segmented into

• Oral
• Parenteral

Based on distribution channel, multiple sclerosis drugs market can be segmented into

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Based on drug class, multiple sclerosis drugs market can be segmented into

• Disease Modifying Drugs (DMDs)
• Steroids
• Others

The global multiple sclerosis drugs market is majorly influenced by increased number of patients from secondary progressive relapsing-remitting multiple sclerosis. The awareness in identifying multiple sclerosis disease conditions increased because of organizations such as National MS society and Multiple Sclerosis Association of America (MSAA) are actively involved in educating the people regarding associated symptoms and increasing the awareness. The presence of strong pipeline drugs such as pleneva (BTG international Ltd.), cladribine (Merck &Co., Inc) and their expected commercialization witness to boost the market share. Companies also actively involved in collaborating with other drug manufacturers for development of drugs such as ampryra (Acordda Therapeutics and Biogen Idec), laquinimod (Active Biotech and Teva Pharmaceuticals), and rebif (Merck Serono and Pfizer). These initiatives are enabling the manufactures to strengthen their product share in Multiple sclerosis drug market. In Multiple sclerosis drug market segments immunomodulators are predominantly used compared to other segments. On the arrival of the easier-to-use oral drugs, market share of the injectables has decreased.

Geographically multiple sclerosis drug market segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Among these regions North America is more dominating in Multiple sclerosis drug market. Multiple sclerosis related healthcare estimated more than $10bn in U.S. In North America, U.S. dominates overall market and followed by Canada. In Europe countries like Italy, Spain, and the UK holds the major share due to increased prevalence rate of multiple sclerosis. In Asian pacific region developing countries like regions like India China have advantage for the drug makers over the developed markets due to low cost of production and high availability of talent pool. Because most of the multiple sclerosis drug are biomedical drugs and requires more investment and time for developing biological products.

Key market players in multiple sclerosis drug market include Novartis AG (Switzerland), Teva Pharmaceutical industries Ltd. (Israel), Biogen, Inc. (U.S.), Merck & Co., Inc. (U.S.), Sanofi S.A. (France), Acorda Therapeuitics (U.S.), Pfizer Inc. (U.S.), Bayer AG (Germany) and Medtronic plc (Questcor Pharmaceuiticals) (U.S.) to name a few.

In March 2017, U.S. FDA approved ocrevus (Genetech USA,Inc.) to treat adult patients with relapsing form of multiple sclerosis and primary progression multiple sclerosis(PPMS).And this is first to treat this type of Multiple Sclerosis

In 2015, Bayer Healthcare Pharmaceuticals Inc. launched betaconnect, the first electric auto injector to treat of multiple sclerosis

REPORT OUTLINE:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET INTRODUCTION

2.1. Global Multiple Sclerosis Drugs Market – Taxonomy
2.2. Global Multiple Sclerosis Drugs Market –Definitions
  2.2.1. Drug Class
  2.2.2. Distribution Channel

3. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Multiple Sclerosis Drugs Market Dynamics – Factors Impact Analysis
3.6. Global Multiple Sclerosis Drugs Market – Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
3.7. Global Multiple Sclerosis Drugs Market – Recent Product Launches

4. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Disease Modifying Drugs (DMDs)
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Steroids
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Others
  5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis

6. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Oral
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Parenteral
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis

7. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL MULTIPLE SCLEROSIS DRUGS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA MULTIPLE SCLEROSIS DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1.1. Disease Modifying Drugs (DMDs)
    9.1.1.2. Steroids
    9.1.1.3. Others
  9.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Oral
    9.1.2.2. Parenteral
  9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Retail Pharmacies
    9.1.3.2. Hospital Pharmacies
    9.1.3.3. Online Pharmacies
  9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.1.4.1. U.S.
    9.1.4.2. Canada
  9.1.5. North America Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  9.1.6. North America Multiple Sclerosis Drugs Market Dynamics – Trends

10. EUROPE MULTIPLE SCLEROSIS DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Disease Modifying Drugs (DMDs)
    10.1.1.2. Steroids
    10.1.1.3. Others
  10.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Oral
    10.1.2.2. Parenteral
  10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Retail Pharmacies
    10.1.3.2. Hospital Pharmacies
    10.1.3.3. Online Pharmacies
  10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Germany
    10.1.4.2. UK
    10.1.4.3. France
    10.1.4.4. Spain
    10.1.4.5. Italy
    10.1.4.6. Russia
    10.1.4.7. Poland
    10.1.4.8. Rest of Europe
  10.1.5. Europe Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  10.1.6. Europe Multiple Sclerosis Drugs Market Dynamics – Trends

11. ASIA-PACIFIC MULTIPLE SCLEROSIS DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Disease Modifying Drugs (DMDs)
    11.1.1.2. Steroids
    11.1.1.3. Others
  11.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Oral
    11.1.2.2. Parenteral
  11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Retail Pharmacies
    11.1.3.2. Hospital Pharmacies
    11.1.3.3. Online Pharmacies
  11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.1.4.1. Japan
    11.1.4.2. China
    11.1.4.3. India
    11.1.4.4. ASEAN
    11.1.4.5. Australia & New Zealand
    11.1.4.6. Rest of Asia-Pacific
  11.1.5. Asia-Pacific Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  11.1.6. Asia-Pacific Multiple Sclerosis Drugs Market Dynamics – Trends

12. LATIN AMERICA MULTIPLE SCLEROSIS DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Disease Modifying Drugs (DMDs)
    12.1.1.2. Steroids
    12.1.1.3. Others
  12.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Oral
    12.1.2.2. Parenteral
  12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Retail Pharmacies
    12.1.3.2. Hospital Pharmacies
    12.1.3.3. Online Pharmacies
  12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Brazil
    12.1.4.2. Mexico
    12.1.4.3. Argentina
    12.1.4.4. Venezuela
    12.1.4.5. Rest of Latin America
  12.1.5. Latin America Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  12.1.6. Latin America Multiple Sclerosis Drugs Market Dynamics – Trends

13. MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS DRUGS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Disease Modifying Drugs (DMDs)
    13.1.1.2. Steroids
    13.1.1.3. Others
  13.1.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Oral
    13.1.2.2. Parenteral
  13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Retail Pharmacies
    13.1.3.2. Hospital Pharmacies
    13.1.3.3. Online Pharmacies
  13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.4.1. Gulf Cooperation Council (GCC) Countries
    13.1.4.2. Israel
    13.1.4.3. South Africa
    13.1.4.4. Rest of MEA
  13.1.5. MEA Multiple Sclerosis Drugs Market - Opportunity Analysis Index - By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
  13.1.6. MEA Multiple Sclerosis Drugs Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Novartis AG (Switzerland)
  14.2.2. Teva Pharmaceutical industries Ltd. (Israel)
  14.2.3. Biogen, Inc. (U.S.)
  14.2.4. Merck & Co., Inc. (U.S.)
  14.2.5. Sanofi S.A. (France)
  14.2.6. Acorda Therapeuitics (U.S.)
  14.2.7. Pfizer Inc. (U.S.)
  14.2.8. Bayer AG (Germany)
  14.2.9. Medtronic plc (Questcor Pharmaceuiticals) (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS